Kadimastem Ltd.
KDST | TA
Overview
Corporate Details
- ISIN(s):
- IL0011284614
- LEI:
- Country:
- Israel
- Address:
- Pinchas Sapir 3, Weizmann Science Park, 7414003 Nes-Ziona
- Website:
- https://www.kadimastem.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Kadimastem Ltd. is a clinical-stage biotechnology company specializing in the development of regenerative medicine and 'off-the-shelf' allogeneic cell therapies. The company utilizes a proprietary technology platform for the industrial-scale development, manufacturing, and bio-banking of functional human cells derived from embryonic stem cells. Its therapeutic pipeline is primarily focused on creating treatments for debilitating conditions, including neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) and metabolic disorders like diabetes.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Kadimastem Ltd..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2024-05-28 11:41 |
Investor Presentation
Company Presentation
|
English | 4.4 MB | |
| 2024-05-28 11:41 |
Pre-Annual General Meeting Information
Company Presentation
|
Russian | 42.5 KB | |
| 2024-02-12 13:47 |
Regulatory News Service
Excellence Investments Management and Securities will cease to operate as a mar…
|
Hebrew (modern) | 122.7 KB | |
| 2022-12-13 16:05 |
Regulatory News Service
Rights Offering and Identifying Details for New Security-KADIMASTEM R4
|
Hebrew (modern) | 177.9 KB | |
| 2022-08-09 13:00 |
Regulatory News Service
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
|
English | 12.0 KB | |
| 2022-06-08 13:00 |
Regulatory News Service
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards …
|
English | 12.1 KB | |
| 2022-05-30 15:10 |
Regulatory News Service
Kadimastem Awarded Patent in Japan for AstroRx For ALS and Drug Screening
|
English | 10.6 KB | |
| 2022-05-18 13:00 |
Regulatory News Service
Kadimastem Expands R&D Program to Include Multiple Sclerosis
|
English | 9.5 KB | |
| 2022-03-03 14:05 |
Regulatory News Service
Kadimastem Receives Grant for a Total Budget of NIS 10 Million ($3.1 million) f…
|
English | 10.4 KB | |
| 2021-12-13 13:00 |
Capital/Financing Update
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel I…
|
English | 10.6 KB | |
| 2021-10-26 07:49 |
Share Issue/Capital Change
Kadimastem Raises $5 million In Private Placement
|
English | 10.5 KB | |
| 2021-10-25 14:09 |
Share Issue/Capital Change
Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement
|
English | 10.5 KB | |
| 2021-10-12 15:55 |
Legal Proceedings Report
Kadimastem Holds Successful Preliminary Meeting with the FDA (INTERACT)
Regar…
|
English | 9.5 KB | |
| 2021-05-02 19:15 |
Investor Presentation
Company Presentation May 2021
|
English | 3.0 MB | |
| 2021-05-02 19:15 |
Report Publication Announcement
Company Presentation May 2021
|
Russian | 42.5 KB |
Automate Your Workflow. Get a real-time feed of all Kadimastem Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Kadimastem Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
